Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402059 | 0.84 | PDE5A (0.61) | GRIN1GRIN2BMMP13KDM4ELMNA | |
| SCHEMBL941179 | 0.82 | PDE5A (0.64) | KDM4ELMNAROCK2KMT2A | |
| SCHEMBL13367923 | 0.81 | MMP13 (0.53) | GRIN1GRIN2BMMP13KMT2AALPL | |
| SCHEMBL10054289 | 0.80 | KMT2A (0.50) | GRIN1GRIN2BMMP13KMT2AALPL | |
| SCHEMBL401645 | 0.79 | PDE5A (0.72) | MMP13KDM4EKMT2A | |
| SCHEMBL23882602 | 0.79 | ROCK2 (0.64) | MMP13KDM4ELMNAHSD17B10ROCK2 | |
| SCHEMBL17888978 | 0.78 | MMP13 (0.58) | GRIN1GRIN2BMMP13KMT2A | |
| SCHEMBL4930565 | 0.78 | MMP13 (0.78) | MMP13 | |
| SCHEMBL27694097 | 0.78 | TNKS (0.58) | KMT2A | |
| SCHEMBL399659 | 0.76 | PDE5A (0.59) | MMP13KDM4EHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CNR2, CYP2C9, CYP2C8 | GRIN1 1253/4885GRIN2B 859/4885MMP13 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.